PRINCETON, N.J., June 17 /PRNewswire-FirstCall/ -- Cytogen Corporation , a product-driven biopharmaceutical company, today announced that it will present at the BIO 2005 Annual International Convention being held June 19-22, 2005 at the Pennsylvania Convention Center in Philadelphia, PA. The Company’s presentation will take place as part of the Business Forum on Tuesday, June 21, 2005 at 10:00 a.m. in Room D.
The presentation, which will be made by Michael D. Becker, Cytogen’s President and Chief Executive Officer, will review highlights of Cytogen’s continuing development programs for QUADRAMET(R) (samarium Sm-153 lexidronam injection). QUADRAMET, Cytogen’s flagship product, is a fast-acting, long- lasting non-opioid therapeutic alternative for the relief of pain due to metastatic bone disease arising from prostate, breast, multiple myeloma and other types of cancer.
Mr. Becker will also chair the panel session, “Next Generation of Targeted Radiotherapy Drugs Emerges from the Clinical Pipeline,” which will take place on Monday, June 20, 2005 from 2:15 p.m. to 3:45 p.m. in Room 108A during a BIO 2005 Break-Out Session in the “Cancer” track. The panel session will highlight issues related to the successful commercialization of targeted radiotherapy in oncology.
ABOUT QUADRAMET
QUADRAMET is an oncology product that pairs the targeting ability of a small molecule, bone-seeking phosphonate (EDTMP) with the therapeutic potential of radiation (samarium Sm-153). Skeletal invasion by prostate, breast, multiple myeloma, and other cancers often creates an imbalance between the normal process of bone destruction and formation. QUADRAMET selectively targets such sites of imbalance, thereby delivering radioactivity to areas of the skeleton that have been invaded by metastatic tumor.
QUADRAMET has many characteristics which the Company believes are advantageous for the treatment of metastatic bone disease, including early onset of pain relief, predictable and reversible bone marrow toxicity or myelosuppression, ease of administration, and length of pain relief, lasting, on average, four months with a single injection. QUADRAMET is administered as an intravenous injection on an outpatient basis, and exhibits selective uptake in bone with little or no detectable accumulation in soft tissue.
NOTE:
QUADRAMET is indicated for the relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan. A copy of the full prescribing information for QUADRAMET may be obtained in the U.S. from Cytogen Corporation by calling toll-free 800-833-3533 or by visiting the web site at http://www.cytogen.com, which is not part of this press release.
ABOUT CYTOGEN CORPORATION
Founded in 1980, Cytogen Corporation of Princeton, NJ is a product-driven biopharmaceutical company that develops and commercializes innovative molecules that can be used to build leading franchises. Cytogen’s marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam injection) and PROSTASCINT(R) (capromab pendetide) kit for the preparation of Indium In-111 capromab pendetide in the United States. Cytogen also has exclusive United States marketing rights to COMBIDEX(R) (ferumoxtran-10) for all applications, and the exclusive right to market and sell ferumoxytol (previously Code 7228) for oncology applications in the United States. Cytogen’s development pipeline consists of therapeutics targeting prostate-specific membrane antigen (PSMA), a protein highly expressed on the surface of prostate cancer cells and the neovasculature of solid tumors. Full prescribing information for the Company’s products is available at http://www.cytogen.com or by calling 1-800- 833-3533. For more information, please visit the Company’s website at http://www.cytogen.com, which is not part of this press release.
This press release contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and investors are cautioned not to put any undue reliance on any forward-looking statement. There are a number of important factors that could cause Cytogen’s results to differ materially from those indicated by such forward-looking statements. In particular, Cytogen’s business is subject to a number of significant risks, which include, but are not limited to: the risk of obtaining the necessary regulatory approvals; the risk of whether products result from development activities; the risk of shifts in the regulatory environment affecting sales of Cytogen’s products such as third-party payor reimbursement issues; the risk associated with Cytogen’s dependence on its partners for development of certain projects, as well as other factors expressed from time to time in Cytogen’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with Cytogen’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Cytogen undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Cytogen Corporation
CONTACT: Media
Web site: http://www.cytogen.com/